This page shows the latest Yescarta news and features for those working in and with pharma, biotech and healthcare.
The main focus of that deal was Kite’s Yescarta (axicabtagene ciloleucel), the company’s first CAR-T therapy, which was approved in October 2017 for the treatment of adults with ... Yescarta was joined by Kite’s second CAR-T therapy Tecartus
Gilead’s Kite division presented new phase 2 data for its CAR T therapy Yescarta at ASH 2020 in relapsed or refractory high-risk large B-cell lymphoma (LBCL), a potential ... In the phase 2 ZUMA-12 study, after a single infusion of Yescarta
Sales of its Kite-partnered CAR-T cell therapy Yescarta (axicabtagene ciloleucel) climbed to $156m in the quarter, an increase on the $120m it generated for the same period in 2019.
Moreover, unlike currently-approved CAR-T therapies for cancer like Novartis’ Kymriah (tisagenlecleucel) and Gilead/Kite’s Yescarta (axicabtagene ciloleucel) which are approved for haematologic cancers, TCRs has the potential to
If it does receive approval, liso-cel will come onto the market after rival Novartis’ Kymriah (tisangenlecleucel) and Gilead Sciences’ Yescarta (axicabtagene ciloleucel). ... BMS alleged that Kite scientists copied research from the scientists at
Gilead/Kite’s approved CAR-T therapy Yescarta (axicabtagene ciloleucel) is available for the treatment of diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma.
More from news
Approximately 12 fully matching, plus 53 partially matching documents found.
as Kymriah and Yescarta.
It has brought to market not one but two groundbreaking drugs in hepatitis C, Harvoni, and in diffuse large B cell lymphoma, Yescarta, one of the first CAR-T therapies to
years. Kymriah’s US list price is $475, 000 while Gilead’s rival drug, Yescarta, is priced at $373, 000 (with European prices substantially lower than this).
can make it on to the market early – agreements on the two CAR-T drugs, Novartis’ Kymriah and Gilead’s Yescarta providing an encouraging sign.
Cell and gene therapies are currently expensive to manufacture. We do not believe that recently marketed products, with US prices ranging from $373, 000 for Yescarta to $850, 000 for Luxturna,
More from intelligence
Approximately 0 fully matching, plus 11 partially matching documents found.
In August, Novartis’ revolutionary CAR-T therapy, Kymriah, was approved. This was quickly followed by the approval of Kite’s Yescarta in October.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...